Physician profile
Leonard Timpone
NPI 1255375093
$6,244.17
in general payments reported to CMS, 2019-2025
26 companies · $641 in 2025
The $641 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $769 · 2020: $823 · 2021: $1,373 · 2022: $880 · 2023: $798 · 2024: $961 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,399.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,325.36 | 2019-2025 | Jardiance, Tradjenta, Glyxambi |
| Amarin Pharma, INC. | $746.86 | 2019-2021 | |
| Pfizer INC. | $739.46 | 2019-2025 | |
| Amgen INC. | $407.60 | 2023-2025 | Repatha, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $406.96 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $322.07 | 2020-2024 | Breztri, Lokelma, Farxiga |
| Glaxosmithkline, LLC. | $317.93 | 2020-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $271.44 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $243.24 | 2021-2022 | |
| Novo Nordisk INC | $233.25 | 2020-2025 | Ozempic, Rybelsus |
| Sunovion Pharmaceuticals INC. | $186.86 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $184.43 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $178.28 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $119.23 | 2025 | |
| Acadia Pharmaceuticals INC | $100.71 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $67.33 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.86 | 2019-2025 | Xifaxan |
| Sanofi Pasteur INC. | $59.11 | 2021-2023 | |
| Kowa Pharmaceuticals America, INC. | $52.45 | 2020-2021 | |
| Esperion Therapeutics, INC. | $46.66 | 2021-2023 | Nexletol |
| Eisai INC. | $45.07 | 2021-2025 | |
| Allergan, INC. | $41.65 | 2019-2020 | |
| Seqirus USA INC | $25.04 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Intra-Sana Laboratories | $22.96 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Evoke Pharma, INC. | $17.48 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $16.88 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Timpone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.